HYBRID EVENT: You can participate in person at Paris, France or Virtually from your home or work.

3rd Edition of International Heart Congress

June 05-07,2025 | Hybrid Event

June 05 -07, 2025 | Rome, Italy
Heart Congress 2023

Role of non-invasive diagnostic modalities in detection of allograft rejection post cardiac transplantation

Kishore Gupta, Speaker at Heart Conferences
Marengo CIMS, India
Title : Role of non-invasive diagnostic modalities in detection of allograft rejection post cardiac transplantation

Abstract:

Heart transplantation continues to be the definitive treatment for end-stage heart failure. With the median survival of 15 years among first-year survivors, allograft rejection (AR) and allograft injury after cardiac transplantation still remains a challenging obstacle to post surgery long-term survival. So far, the invasive diagnostics in form of endomyocardial biopsy (EMB) remains the gold standard surveillance tool for rejection following heart transplant.

Conventional tests such as electrocardiography, echocardiography, and serum biomarkers have low sensitivity and specificity to detect AR and are not recommended as potential alternatives to EMB. But donor derived cell free DNA (cfDNA), known as liquid biopsy, is rapidly becoming a highly useful tool for surveillance of solid organ transplant rejection. It is more sensitive in picking antibody-mediated rejection than ACR. cfDNA/RNA studies can potentially replace EMB in future. CMR-based surveillance strategy in addition to routine echocardiography for ACAR in the first year after orthotopic heart transplantation is also feasible compared with EMB-based surveillance. Gene expression profiling of the genes involved in cellular rejection has a high negative predictive value of 99.6% for moderate to severe cellular rejection but poor positive predictive value and unclear relevance to antibody-mediated rejection.

Some of the novel approaches successfully tested in preclinical and clinical models while some in the developmental phases, may lead to a prolongation of patient’s and heart allograft survival and a step closer to a new diagnostic standard for AR.

 

Audience Take Away Notes
Current updates and developments in the field of cardiac rejection monitoring

Incorporation of newer diagnostic modalities in their setup for diagnosis of heart transplant rejection algorithms

Updating of allograft rejection algorithms

Earlier detection of rejection and better outcomes post cardiac transplantation

Biography:

Dr. Kishore Gupta is self driven, focused, hard working, qualified, registered surgeon who completed his graduation at Medical college Loni, Maharashtra in 2011 and then joined the superspeciality studies in 2013 at Fortis healthcare Mohali. After completing the studies in 2017, did one year of senior residency at the same institution. He joined Care Instititute of Medical Sciences, Ahmedabad, Gujarat in 2019 as Consultant Cardiac Surgeon. He received MNAMS degree in 2020. He has completed Masters in Healthcare and Management in the year 2022. He has obtained the post of Transplant surgeon at the same institute. He has more than 10 publications in national and international journals.

 

Watsapp